Back to Search
Start Over
Merck announces results from KEYNOTE-756 trial at ESMO Congress
- Source :
- The Fly. October 20, 2023
- Publication Year :
- 2023
-
Abstract
- Merck announced the first presentation of results from the neoadjuvant part of the Phase 3 KEYNOTE-756 trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.769628853